Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer aims to spot prostate cancer more clearly

NCT ID NCT03995888

Diagnosis Sponsor: Blue Earth Diagnostics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new radioactive imaging agent called rhPSMA-7.3 (18F) in 24 people: some healthy volunteers and some with prostate cancer. The goal was to check safety and see how the agent spreads in the body and how well it lights up cancer on PET scans. The study is complete, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rhPSMA-7.3 (18F) injection
What this could lead to
If successful, this could lead to a more accurate PET scan to detect prostate cancer, helping doctors see where the cancer is in the body.
What could go wrong
This is an early phase 1 study with only 24 people, so it is too small to prove the scan works better than current methods. The main goal is safety, not yet effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

24 people

The number who actually took part.

Started

Jun 2019

Finished

Apr 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: Healthy Volunteers 1. Male and females 21-65 years. 2. Clinically acceptable medical history Key Exclusion Criteria: Healthy Volunteers 1. Received ionising radiation exposure from clinical trials or medical examinations or treatment in the last 12 months. 2. Suffers from claustrophobia. 3. Bilateral hip prostheses. Key Inclusion Criteria: Patients 1. Male 18-80 years. 2. Histologically confirmed adenocarcinoma of the prostate 3. Clinically acceptable medical history 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Key Exclusion Criteria: Patients 1. Biopsy 28 days prior to enrollment. 2. Extensive metastatic disease. 3. Underlying disease which might confound interpretation. 4. Bilateral hip prostheses. 5. High energy (\>300 Kiloelectron Volt (keV)) gamma-emitting radioisotope administered within five physical half-lives, or any intravenous iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days prior to study drug administration. 6. X-ray contrast agent (\<24 hr for intravenous agents and \<5 days for oral agents). 7. History of claustrophobia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Clinical Research Services Turku - CRST Oy

    Turku, FI-20520, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.